Holen Sie sich die Stockscreener-App
727.20
2.55%
-19.00
Handel nachbörslich:
727.00
-0.20
-0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$746.20
Offen:
$733.19
24-Stunden-Volumen:
8.26M
Relative Volume:
2.64
Marktkapitalisierung:
$683.37B
Einnahmen:
$40.86B
Nettoeinkommen (Verlust:
$8.37B
KGV:
134.19
EPS:
5.4193
Netto-Cashflow:
$-2.28B
1W Leistung:
-12.64%
1M Leistung:
-20.78%
6M Leistung:
-5.56%
1J Leistung:
+22.90%
1-Tages-Spanne:
$711.40
$734.00
1-Wochen-Bereich:
$711.40
$833.99
52-Wochen-Spanne:
$561.65
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Cramer's Lightning Round: Eli Lilly is a buy - NBC Philadelphia
Lilly pill cuts genetic form of cholesterol nearly 86% in study - Reuters
Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels - Seeking Alpha
Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial - TipRanks
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose - Investors | Eli Lilly and Company
Eli Lilly follows J&J in suing Biden administration over 340B rebates - Healthcare Dive
Tesla, Eli Lilly lead market cap stock movers on Monday By Investing.com - Investing.com South Africa
Revisto, Inc announced that it has received $4 million in funding from LiveOak Ventures, Eli Lilly and Company, TAU VENTURES, Arkin Digital Health - Marketscreener.com
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure - Yahoo Finance
Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints - Marketscreener.com
Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients (NYSE:LLY) - Seeking Alpha
3 Growth Stocks You Can Buy Right Now Without Any Hesitation - The Motley Fool
Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Colorado Springs Gazette
Eli Lilly: positive results for tirzepatide - Marketscreener.com
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF - Clinical Trials Arena
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now - The Motley Fool
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand? - Yahoo! Voices
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity - Investors | Eli Lilly and Company
Eli Lilly Says HHS Ignores Drug Discount Double-Dipping - Law360
Lilly Sues U.S. to Change Hospital Drug Discount Payments - The Wall Street Journal
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Lilly Sues HHS for Ending Planned 340B Drug Program Cash Rebates - Bloomberg Law
Eli Lilly sues to change hospital drug discount payments, WSJ reports - TipRanks
Eli Lilly and Co (NYSE:LLY) Sues Federal Health Agency over Hospital Drug Discounts - TipRanks
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program - Yahoo! Voices
Eli Lilly: sues US federal agency - Marketscreener.com
Lilly sues US agency over blocking of drug-rebate program - Reuters
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead? - The Motley Fool
Lilly Statement on New 340B Litigation - Investors | Eli Lilly and Company
ELI LILLY AND COMPANY - Marketscreener.com
Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows - Verywell Health
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows - Benzinga
Lilly expands research in Singapore with focus on sleep quality - Indianapolis Business Journal
Eli Lilly Stock: Is LLY Stock A Sell After Its Disastrous Third-Quarter Report? - Investor's Business Daily
Smart toilet, AI platform among tech in use at drugmaker Eli Lilly’s new $42m hub in S’pore - The Straits Times
Eli Lilly: conclusive phase III trial on tirzepatide - Marketscreener.com
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes - Clinical Trials Arena
Lilly Expands Research in Singapore With Focus on Sleep Quality - BNN Bloomberg
Eli Lilly's Tirzepatide Reduces Type 2 Diabetes Risk by 94% in Long-Term Study - Yahoo Finance
Ozempic MDL Plaintiffs Say Eli Lilly, Novo Nordisk Hid Risks - Law360
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks - Marketscreener.com
Eli Lilly's New Drug Shows Promise In Diabetes Prevention - Finimize
Lilly three-year tirzepatide results show sustained weight loss, diabetes benefits - Seeking Alpha
Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks - Investors | Eli Lilly and Company
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free - Reuters
Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years - FiercePharma
Eli Lilly's SWOT analysis: biopharmaceutical giant's stock poised for growth - Investing.com
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Ex-Dividend Reminder: U.S. Physical Therapy, MMM and Eli Lilly - Nasdaq
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly? - The Motley Fool
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):